Trials / Terminated
TerminatedNCT04842253
HFNC Vs LFNC in Patients with AF Undergoing RFCA Under Deep Sedation.
High Flow Nasal Cannula (HFNC) Versus Standard Low Flow Nasal Cannula (LFNC) in Patients with Atrial Fibrillation Undergoing Radiofrequency Catheter Ablation (RFCA) Under Deep Desaturation.
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 141 (actual)
- Sponsor
- Maastricht University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Oxygen supplementation through high flow nasal cannula (HFNC) may reduce the incidence of desaturation and hypoxemia during deep sedation at radiofrequency catheter ablation (RFCA procedures).This study is designed to test the hypothesis that the incidence of hypoxemia and desaturation in patients with atrial fibrillation undergoing RFCA under deep sedation, is less when using HFNC as compared to use of standard low flow nasal cannula (LFNC).
Detailed description
Desaturation may occur in patients under deep sedation which results in an elevated risk for perioperative adverse events including hypoxemia (1-3). The incidence of hypoxemia was 168 per 1000 in a general procedural sedation and analgesia population (4). The clinical significance of transient episodes of hypoxemia remains debatable. However, many peri-operative incidents are often short-term and limited in nature, but a number of them are a predictor to a serious complication with a permanent injury (5).This study investigates if high flow nasal cannula (HFNC) as compared to low flow nasal cannula (LFNC) will result in a lower incidence of intra-procedural oxygen desaturation and hypoxemia in patients with atrial fibrillation undergoing deep sedation for radiofrequency catheter ablation (RFCA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | High flow nasal cannula | HFNC during deep sedation undergoing radiofrequency ablation for atrial fibrillation. |
Timeline
- Start date
- 2022-01-04
- Primary completion
- 2024-11-18
- Completion
- 2024-11-18
- First posted
- 2021-04-13
- Last updated
- 2025-02-20
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04842253. Inclusion in this directory is not an endorsement.